CD274 and hepatocellular carcinoma: The combination therapy of PD-1/PD-L1 inhibitors with antiangiogenic drugs, such as pembrolizumab plus lenvatinib (5), sintilimab plus bevacizumab (6), and camrelizumab plus apatinib (7), attained good clinical results in advanced HCC patients and improved overall survival (OS) over single-agent therapy.